Ruijian Medical Enters IPO Counseling Phase with Backing from Advant Capital and Vertex Ventures, Submits Filing for Public Offering

On April 24, 2023, the official website of the CSRC showed that Hangzhou Rejoin Medical Group Co., Ltd. (hereinafter referred to as "Rejoin Medical") had filed for IPO coaching. The coaching institution was Sinolink Securities, and the dispatched institution was Zhejiang CSRC Bureau.

Source of the image: Official website of the CSRC

Official website information shows that Rejoin Medical was established in 2003. It is dedicated to providing simpler and more reliable comprehensive solutions for sports medicine and minimally invasive orthopedic doctors and patients, aiming to build a sustainably developing Rejoin Medical for 105 years. Rejoin Medical is a national high-tech enterprise specializing in the research and development, production, and sales of medical device products for sports medicine and minimally invasive orthopedics.

Rejoin Medical, headquartered in Hangzhou, China, operates the REJOIN Academy along with branches in Shanghai and Beijing, and a subsidiary in Hong Kong. Its sales and service network spans over 60 countries and more than 400 regions across Europe, the Americas, Asia-Pacific, the Middle East, and Africa, gaining widespread recognition in both the Chinese and international markets. Over 80% of the company’s R&D, operations, and market sales management team consists of top talents from globally renowned medical device companies such as Johnson & Johnson, Smith & Nephew, and Medtronic. Equity incentives cover more than 50% of professional and managerial staff.

According to the PharmaCube InvestGo investment and financing database, Rejoin Medical has completed two rounds of financing worth hundreds of millions of yuan, with investors including well-known capital firms such as Yada Capital and Vertex Ventures.

The IPO tutoring process of Rejoin Medical disclosed in the tutoring filing report is as follows: